Abciximab and tirofiban produce similar outcomes six months after PCI

In the TARGET trial of 4809 patients undergoing stenting, the primary end point (composite of death, nonfatal myocardial infarction, or urgent target vessel revascularization) was significantly lower with abciximab compared to tirofiban at 30 days, but no difference was apparent at six months.